Healthcare - Press Releases

-Drugs found to be safe and effective overall despite some risk of eye damage

No Shareholder Action Required at this Time

SUZHOU, China, March 5, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL. CS5001 is also being evaluated as both a monotherapy and in combination with a PD-L1 inhibitor for advanced solid tumors in an ongoing global multi-center clinical trial.

HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk following curative resection or ablation.

- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions -

Chelsea Handler, Naomi Watts, Katie Couric, Christy Turlington Burns, Dr. Jessica Shepherd, Dr. Sharon Malone, Stacy London, Sophia Bush, Dr. Jennifer Ashton, Hannah Bronfman, Emma Lovewell, Scott Galloway, Elaine Welteroth, Chip Conley, and more to amplify key issues shaping the future of health.

Deploys capital towards opportunities in AI, quantum computing, digital assets, defence, biotechnology and more

ZEISS VISUMAX 800 with SMILE pro software ZEISS (PRNewsfoto/Carl Zeiss Meditec)

Sold VHCIX & VENAX, Bought VFLO

ARLINGTON, Va., Feb. 26, 2025 /PRNewswire/ -- This week, the House of Representatives passeda budget resolution instructing the House Energy and Commerce Committee to cut approximately $880 billion over the next decade, with the majority of these reductions expected to come from Medicaid. These drastic cuts would severely weaken a program that provides essential healthcare to nearly 80 million people, including pregnant women, babies, and children. If enacted, these changes could lead to reduced Medicaid eligibility, fewer covered services, and new barriers to care, leaving millions without access to critical prenatal, postpartum, and infant health services. At a time when the US already faces an alarming maternal and infant health crisis, these cuts would put even more lives at risk.

MEXICO CITY, Feb. 26, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the fourth quarter and full year ended December 31, 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned.

LOS ANGELES, Feb. 26, 2025 /PRNewswire/ -- TheWorld Brain Mapping Foundation (WBMF) is set to make a powerful comeback. On March 1st, it will host its 22nd Annual Gathering for the Cure (GFC) award gala at the Millennium Biltmore Hotel in Los Angeles. The red carpet will take place from 6:00 to 8:00 p.m., followed by the award banquet from 8:00 to 11:00 p.m.

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.

TIANJIN, Chine, 27 fvrier 2025 /PRNewswire/ -- Le dbat sur les CSM, qui oppose les cellules stromales msenchymateuses aux cellules souches msenchymateuses, s'est poursuivi pendant prs de deux dcennies (depuis 2006), constituant l'obstacle majeur l'tude et l'application clinique des CSM. La principale question concernait les cellules souches msenchymateuses, dont l'application clinique ne peut tre approuve sans un test d'innocuit approfondi (par exemple, formation de tumeurs), mais toutes les tudes prcliniques ont prouv que les CSM actuellement prpares et utilises sont sres et ne posent pas les problmes lis aux cellules souches, tant donn qu'il s'agit bien de cellules stromales msenchymateuses, et non de cellules souches. Mais o est l'approbation ?

TIANJIN, China, 27 de febrero de 2025 /PRNewswire/ -- El debate sobre las MSC, clulas estromales mesenquimales versus clulas madre mesenquimales, ha continuado durante ms de dos dcadas (desde 2006), siendo el principal obstculo para el estudio de las MSC y su aplicacin clnica. El principal problema se centra en que las clulas madre mesenquimales no podran aprobarse para su aplicacin clnica sin una prueba exhaustiva de seguridad (por ejemplo, formacin de tumores), pero todos los estudios preclnicos demostraron que las MSC que se preparan y utilizan actualmente son seguras sin las preocupaciones relacionadas con las clulas madre, de modo que son clulas estromales mesenquimales, no clulas madre. Sin embargo, dnde est la aprobacin?

TIANJIN, China, 27. Februar 2025 /PRNewswire/ -- Die Debatte ber mesenchymale Stromazellen (MSCs) im Vergleich zu mesenchymalen Stammzellen hlt seit mehr als zwei Jahrzehnten (seit 2006) an und ist das grte Hindernis fr die Erforschung und klinische Anwendung von MSCs. Das Hauptproblem besteht darin, dass mesenchymale Stammzellen ohne eine grndliche Prfung auf Sicherheit (z.B. Tumorbildung) nicht fr die klinische Anwendung zugelassen werden knnen. Alle prklinischen Studien haben jedoch bewiesen, dass die derzeit hergestellten und verwendeten MSZ sicher sind, ohne die fr Stammzellen relevanten Bedenken, sodass es sich um mesenchymale Stromazellen und nicht um Stammzellen handelt. Doch wo bleibt die Zulassung?

TIANJIN, China, Feb. 26, 2025 /PRNewswire/ -- The debate on MSCs, mesenchymal stromal cells versus mesenchymal stem cells, continued for more than two decades (since 2006), being the major obstacle for MSCs study and clinical application. The major issue focuses on mesenchymal stem cells could not be approved for clinical application without a thorough test for safety issue (e.g. tumor formation), but all pre-clinical studies proved the MSCs currently prepared and used are safe without the concerns relevant to stem cells, so that they are mesenchymal stromal cells, not stem cells. However, where is the approval?

STOCKHOLM, Feb. 27, 2025 /PRNewswire/ -- Sobi (STO: SOBI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant (emapalumab-Izsg) for use in adult and paediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still's disease with an inadequate response or intolerance toglucocorticoids, or with recurrent MAS.The application was granted Priority Review with a PDUFA date of June 27, 2025.

LINKPING, Sweden, Feb. 27, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra(STO: SECT B) invites investors, analysts, and the media to a presentation of the company's nine-month report with President Torbjrn Kronander and CFO Jessica Holmquist.

RICHMOND, Va., Feb. 27, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company's AGM in May 2025.

SOUL, Jun Krea a NEWPORT BEACH, Kalifornia, 27. februra 2025 /PRNewswire/ - Spolonos Medit (www.medit.com), globlny lder v oblasti digitlnej stomatolgie, je pripraven spsobi revolciu v digitlnom pracovnom postupe All-on-X, m sa stane dostupnejm, efektvnejm a intuitvnejm pre pouvateov skenerov znaky Medit.

SEOUL, South Korea and NEWPORT BEACH, Calif., Feb. 27, 2025 /PRNewswire/ -- Medit (www.medit.com), a global leader in digital dentistry, is set to revolutionize the digital All-on-X workflow, making it more accessible, efficient, and intuitive for Medit scanner users.

SEOUL, Core du Sud et NEWPORT BEACH, Californie, 27 fvrier 2025 /PRNewswire/ -- Medit (www.medit.com), leader mondial de la dentisterie numrique, s'apprte rvolutionner le flux de travail numrique All-on-X, en le rendant plus accessible, plus efficace et plus intuitif pour les utilisateurs de scanners Medit.

VoxCell BioInnovation Inc.

OXFORD, England, Feb. 27, 2025 /PRNewswire/ -- Brainomix, a pioneer in stroke AI imaging software and European market leader, has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology. The collaboration aims to enhance stroke care for patients across Western Europe by integrating cutting-edge artificial intelligence (AI) solutions into clinical practice, expanding access to life-changing treatments and improving patient outcomes.